RALPH LISSAUR: Open Payments
NPI 1245287960 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,006 in 52 payments from 12 companies in 2025. Trend: 2023 $1,122 · 2024 $1,003 · 2025 $1,006
Food & beverage: $1,006
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $253 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $157 |
| Neurocrine BioSciences, Inc. | 2 | $143 |
| ABBVIE INC. | 9 | $137 |
| E.R. Squibb & Sons, L.L.C. | 3 | $65 |
| Lundbeck LLC | 2 | $54 |
| Alkermes, Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 2 | $37 |
| Almatica Pharma LLC | 2 | $30 |
Products named: REXULTI, CAPLYTA, INGREZZA, VRAYLAR, ABILIFY ASIMTUFII, COBENFY, ARISTADA, Auvelity.
Industry payments across CA — which companies pay providers there.
